Dr. Jedd Wolchok has been appointed as the Meyer Director of the Sandra and Edward Meyer Cancer Center and Dr. Taha Merghoub as Deputy Director, effective September 12.
Jedd Wolchok, M.D., Ph.D., Professor of Medicine, Division of Hematology and Medical Oncology, is an internationally renowned medical oncologist whose innovations in immunotherapy have revolutionized melanoma treatment. Dr. Wolchok’s advances have included participating in the clinical development of the U.S. Food and Drug Administration–approved immunotherapy ipilimumab for advanced melanoma, and he recently designed and led a global phase III trial of immune checkpoint–blocking antibodies aimed at reactivating the immune response to melanoma. After initial studies of these approaches for melanoma, continued findings have led to therapeutic success in multiple cancers. Before joining Weill Cornell Medicine, Dr. Wolchok served as Chief of the Immuno-Oncology Service and the Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center.
In his new role, Dr. Wolchok will lead an expansive multidisciplinary research and clinical enterprise, recruit cancer researchers and clinicians with a focus on enhancing faculty diversity, broaden the reach of health care to diverse patient populations, and bolster educational programs to train generations of physicians and scientists.
Taha Merghoub, Ph.D., Professor of Immunology Research in Medicine, Weill Cornell Medicine, has been appointed as the Meyer Cancer Center’s Deputy Director. Dr. Merghoub has been Dr. Wolchok’s scientific partner at Memorial Sloan Kettering for over 15 years. He has also been recruited as the Margaret and Herman Sokol Professor of Oncology Research as well as Professor of Pharmacology and will lead a laboratory at Weill Cornell Medicine that investigates the development of immune-based therapies to treat cancer.